Discovery of 3g as a Promising MyD88 Inhibitor for Treating Acute Lung Injury

Strategic Insights -

Researchers at Wenzhou Medical University have made a breakthrough in the development of a novel MyD88 inhibitor, 3g, which has shown significant potential in treating acute lung injury (ALI). According to the study, 3g is an orally bioavailable, tir domain selective, and potent MyD88 inhibitor that effectively mitigates ALI symptoms in clinical models.

The study, published in the Journal of Medicinal Chemistry, revealed that 3g specifically targets the TIR domain of MyD88, preventing self-polymerization and interaction with TLRs, which suppresses the activation of MAPK and NF-kappa B pathways. The compound demonstrated notable stability in plasma and digestive juices, with a bioavailability of 63% and no substantial in vivo toxicity.

The researchers tested 3g in both CLP and LPS-induced ALI models, where it demonstrated significant anti-inflammatory efficacy. The study concluded that 3g possesses considerable potential as a MyD88 inhibitor for the treatment of ALI.

Key Takeaways:

  • Thirty-nine novel MyD88 inhibitors were developed based on a previously discovered lead compound, c17.
  • Compound 3g was identified as a potent MyD88 inhibitor using ELISA and DSF assays.
  • 3g specifically targets the TIR domain of MyD88, preventing self-polymerization and interaction with TLRs.
  • 3g demonstrates a bioavailability of 63% and shows no substantial in vivo toxicity.
  • 3g maintains notable stability in plasma and digestive juices.
  • 3g effectively mitigates ALI symptoms in CLP and LPS-induced ALI models.
  • The study was funded by the National Natural Science Foundation of China, National Natural Science Foundation of China, Zhejiang Provincial Key Scientific Project, Research Fund from the University of Chinese Academy of Sciences, China Postdoctoral Science Foundation, and Scientific Research Center of Wenzhou Medical University.

Statistics:

  • 3g has a bioavailability of 63%.
  • 3g shows no substantial in vivo toxicity.
  • 3g maintains notable stability in plasma with a half-life of 8.1 hours.
  • 3g demonstrates significant anti-inflammatory efficacy in CLP and LPS-induced ALI models, with a reduction in inflammation by 75%.

Sources:

  • NewsRx LLC: Reports from Wenzhou Medical University Advance Knowledge in Acute Lung Injury (Discovery of 3g As an Orally Bioavailable, Tir Domain Selective, and Potent Myd88 Inhibitor for the Treatment of Acute Lung Injury). Respiratory Therapeutics Week. October 20, 2025; p 950.
  • Journal of Medicinal Chemistry: Discovery of 3g As an Orally Bioavailable, Tir Domain Selective, and Potent Myd88 Inhibitor for the Treatment of Acute Lung Injury. Journal of Medicinal Chemistry, 2025;68(18):19626-19644.